{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:45:39Z","timestamp":1789670739049,"version":"4.0.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Serum neurofilament light chain (sNfL) is a biomarker of neuroaxonal destruction that correlates with acute inflammation (AI) in multiple sclerosis (MS). However, in the treatment era, progression without AI is the main driver of long-term disability. sNfL may provide added value in detecting ongoing axonal damage and neurological worsening in patients without AI. We conducted a prospective three-year study on patients with a first MS relapse to evaluate the basal cut-off value predicting early increased disability unrelated to relapses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>sNfL levels and AI presence were measured every 6\u2009months during the first year and the Expanded Disability Status Scale (EDSS) was monitored until the third year. Baseline cohorts were stratified by sNfL levels, using a cut-off derived from patients without AI (absence of clinical relapses, new\/enlarging T2 lesions, or gadolinium enhancement in magnetic resonance imaging) at year one.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fifty-one patients were included. A sNfL cut-off of 11\u2009pg\/mL predicted sustained neurological worsening independent of AI. Patients exceeding this threshold exhibited features of highly active MS (higher proportion of AI, oligoclonal M bands and higher EDSS). Despite AI ablation, sNfL levels persisted elevated and were significantly associated with increased EDSS at baseline and year 3. Patients with low sNfL and concurrent AI (<jats:italic>n<\/jats:italic>\u2009=\u20098) experienced relapses in the optic nerve, brainstem, and spinal cord topographies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>sNfL elevation may detect patients with increased disability even when AI is controlled. This may reveal mechanisms associated with early axonal degeneration and help identify patients at higher risk of progression.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2024.1477335","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T16:02:08Z","timestamp":1730304128000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical trajectories of patients with multiple sclerosis from onset and their relationship with serum neurofilament light chain levels"],"prefix":"10.3389","volume":"15","author":[{"given":"Carlos","family":"Quintanilla-Bord\u00e1s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cubas-N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9ssica","family":"Castillo-Villalba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Carratal\u00e1-Bosc\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Gasque-Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Tortosa-Carreres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Alcal\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"For\u00e9s-Toribio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gorriz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"P\u00e9rez-Miralles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonaventura","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMA Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/NXI.0000000000200025","article-title":"Toward precision phenotyping of multiple sclerosis","volume":"9","author":"Pitt","year":"2022","journal-title":"Neurology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm10040868","article-title":"Assessment of disability progression independent of relapse and brain MRI activity in patients with multiple sclerosis in Poland","volume":"10","author":"Kapica-Topczewska","year":"2021","journal-title":"J Clin Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1093\/BRAIN\/AWAC016","article-title":"How patients with multiple sclerosis acquire disability","volume":"145","author":"Lublin","year":"2022","journal-title":"Brain"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s41747-020-00186-x","article-title":"Ultra-high-field 7-T MRI in multiple sclerosis and other demyelinating diseases: From pathology to clinical practice","volume":"4","author":"Bruschi","year":"2020","journal-title":"Eur Radiol Exp"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum Neurofilament light: a biomarker of neuronal damage in multiple sclerosis","volume":"81","author":"Disanto","year":"2017","journal-title":"Annal Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1212\/WNL.0000000000003653","article-title":"Serum neurofilament is associated with progression of brain atrophy and disability in early MS","volume":"88","author":"Kuhle","year":"2017","journal-title":"Neurology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"103927","DOI":"10.1016\/j.msard.2022.103927","article-title":"Detecting ongoing disease activity in mildly affected multiple sclerosis patients under first-line therapies","volume":"63","author":"Masanneck","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52187","article-title":"Serum glial fibrillary acidic protein predicts disease progression in multiple sclerosis","author":"Madill","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/acn3.51704","article-title":"Associations of sNfL with clinico-radiological measures in a large MS population","volume":"10","author":"Sotirchos","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","article-title":"Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study","volume":"21","author":"Benkert","year":"2022","journal-title":"Lancet Neurol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1159\/000515806","article-title":"Neurofilament light chain levels are associated with disease activity determined by no evident disease activity in multiple sclerosis patients","volume":"84","author":"Szilasiov\u00e1","year":"2021","journal-title":"Eur Neurol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"103590","DOI":"10.1016\/j.ebiom.2021.103590","article-title":"NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study: serum NfL predicts relapse-free progression","volume":"72","author":"Uphaus","year":"2021","journal-title":"EBioMedicine"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","article-title":"Serum glial fibrillary acidic protein compared with Neurofilament light chain as a biomarker for disease progression in multiple sclerosis, JAMA","volume":"80","author":"Meier","year":"2023","journal-title":"Neurology"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1177\/13524585221097296","article-title":"Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis","volume":"28","author":"Brune","year":"2022","journal-title":"Mult Scler J"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/acn3.638","article-title":"Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis","volume":"5","author":"Chitnis","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1177\/1352458518765666","article-title":"Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis","volume":"25","author":"Siller","year":"2019","journal-title":"Mult Scler"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"104118","DOI":"10.1016\/j.msard.2022.104118","article-title":"Oligoclonal M bands unveil occult inflammation in multiple sclerosis","volume":"68","author":"Casanova","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria., the lancet","volume":"17","author":"Thompson","year":"2018","journal-title":"Neurology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nbt.1641","article-title":"Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations","volume":"28","author":"Rissin","year":"2010","journal-title":"Nat Biotechnol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.msard.2014.11.004","article-title":"Cervical cord area measurement using volumetric brain magnetic resonance imaging in multiple sclerosis","volume":"4","author":"Liu","year":"2015","journal-title":"Mult Scler Relat Disord"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1093\/brain\/awq076","article-title":"Evidence for a two-stage disability progression in multiple sclerosis","volume":"133","author":"Leray","year":"2010","journal-title":"Brain"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1093\/brain\/awy154","article-title":"Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis","volume":"141","author":"Barro","year":"2018","journal-title":"Brain"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1001\/jamaneurol.2023.0010","article-title":"Association of Serum Neurofilament Light Chain Levels at disease onset with disability worsening in patients with a first demyelinating multiple sclerosis event not treated with high-efficacy drugs","volume":"80","author":"Monreal","year":"2023","journal-title":"JAMA Neurol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/NXI.0000000000001047","article-title":"Predicting aggressive multiple sclerosis with intrathecal IgM synthesis among patients with a clinically isolated syndrome","volume":"8","author":"Monreal","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1136\/jnnp-2022-329020","article-title":"Serum neurofilament light chain levels predict long-term disability progression in patients with progressive multiple sclerosis","volume":"93","author":"Comabella","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1007\/s00415-023-12135-w","article-title":"Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing\u2013remitting multiple sclerosis: a 20-year follow-up cohort","volume":"271","author":"Arroyo Pereiro","year":"2023","journal-title":"J Neurol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","article-title":"Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease","volume":"25","author":"Preische","year":"2019","journal-title":"Nat Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1007\/s00415-021-10926-7","article-title":"NFL during acute spinal cord lesions in MS: a hurdle for the detection of inflammatory activity","volume":"269","author":"Alcal\u00e1","year":"2022","journal-title":"J Neurol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/ana.26446","article-title":"Contributors to serum NfL levels in people without neurologic disease","volume":"92","author":"Fitzgerald","year":"2022","journal-title":"Ann Neurol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1477335\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T16:02:09Z","timestamp":1730304129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1477335\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":31,"alternative-id":["10.3389\/fneur.2024.1477335"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1477335","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,30]]},"article-number":"1477335"}}